Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let’s stay connected!
To submit a correction request, please visit our Contact Us page.
Maintenance treatment with a novel dendritic cell immunotherapy after chemotherapy did not improve survival outcomes for patients with pleural mesothelioma in the phase II/III DENIM
Results have been presented at the European Society of Cardiology (ESC) Congress 2024 of a meta-analysis that studied the cardiovascular outcomes of glucagon-like peptide-1 receptor
The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating
Why the drug industry’s opaque warnings on price negotiations fall short
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let’s stay connected!
To submit a correction request, please visit our Contact Us page.
Dendritic Cell Therapy Offers No Survival Advantage in Pleural Mesothelioma
Maintenance treatment with a novel dendritic cell immunotherapy after chemotherapy did not improve survival outcomes for patients with pleural mesothelioma in the phase II/III DENIM
ESC 2024: GLP-1RAs lower CV risk in meta-analysis of 32,883
Results have been presented at the European Society of Cardiology (ESC) Congress 2024 of a meta-analysis that studied the cardiovascular outcomes of glucagon-like peptide-1 receptor
A bold approach to pay for weight loss drugs for everyone who needs them
The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating